<DOC>
	<DOCNO>NCT00620308</DOCNO>
	<brief_summary>This human physiologic study evaluate effect new drug call CD-NP individual stable chronic heart failure , focus evaluate response kidneys hormonal system .</brief_summary>
	<brief_title>CD-NP Subjects With Stable Chronic Heart Failure</brief_title>
	<detailed_description>CD-NP novel chimeric natriuretic peptide create combine 22 amino acid human C-type natriuretic peptide ( CNP ) 15-amino-acid C-terminus Dendroaspis natriuretic peptide ( DNP ) . The rationale selecting CNP , natriuretic peptide endothelial cell origin , exhibit predominantly venodilating effect , may minimize systemic hypotension . Moreover , anti-proliferative action also highly desirable property novel cardiovascular drug . However , limitation CNP exert significant renal action , whereas , DNP potently natriuretic diuretic . Thus , CD-NP synthesize goal combine complementary profile CNP DNP single chimeric peptide .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>1 . Male nonpregnant female subject , age 21 , stable chronic HF primary cardiac etiology , rest leave ventricular ejection fraction ( LVEF ) â‰¤ 40 % document within last 2 year , New York Heart Association functional class I III symptoms 2 . Be willing provide inform consent . 1 . Known allergy adverse reaction exogenous natriuretic peptide ( CDNP component , nesiritide , natriuretic peptide , related compound ) . 2 . Women pregnant , breastfeed . 3 . Having receive nesiritide within 7 day prior prior entry study . 4 . Having receive investigational drug device within 30 day prior entry study . 5 . Clinically unstable patient ( e.g . systolic blood pressure &lt; 90 mmHg , ongoing requirement vasopressor mechanical circulatory support , mechanical ventilation ) . 6 . Recent hospitalization decompensated HF recent defibrillation cardiac resuscitation within 30 day prior randomization . 7 . Prior organ transplantation , wait list organ transplantation , ongoing requirement longterm vasoactive support . 8 . Patients guard prognosis unlikely derive meaningful benefit CDNP . 9 . Use sulfonamide , nonsteroidal antiinflammatory drug , probenecid , drug know alter renal function within 5 halflives prior first dose CDNP placebo . 10 . Presence cardiac lesion comorbidities may contraindicate use natriuretic peptide , clinically significant cardiac valvular stenosis , hypertrophic cardiomyopathy , restrictive cardiomyopathy , constrictive pericarditis , primary pulmonary hypertension , uncorrected congenital heart disease contraindicates use vasodilator . 11 . History blood pressure &gt; 190/115 mmHg unexplained syncope within past 3 month . 12 . Symptomatic carotid artery disease , know critical carotid stenosis , stroke within past 3 month 13 . Clinically significant renal artery stenosis 14 . Baseline hemoglobin &lt; 10.0 g/dL . 15 . Serum sodium &lt; 130 mEq/L , potassium &lt; 3.6 mEq/L , magnesium &lt; 1.7 mEq/L . 16 . Elevated aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) least 5 time upper limit normal bilirubin least 3 time upper limit normal 17 . Creatinine clearance ( CrCl ) &lt; 50 ml.min1.1.73m2 , calculate CockcroftGault formula adjust body surface area within past year screening , requirement dialysis . 18 . History alcohol abuse within past 6 month . 19 . Consumption phosphodiesterase5 inhibitor ( sildenafil , vardenafil , tadalafil ) within 72 hour receive CDNP placebo . 20 . Inability communicate effectively study personnel . 21. bmi &gt; 38</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>